Can FDA Do The "Right Thing" On Transparency? Ask A Lawyer
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposals from agency task force include releasing when applications are submitted and withdrawn along with FDA reasons for refuse-to-file and complete response letters.
You may also be interested in...
Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say
Need for informed prescribing demands that products include the data that support biosimilarity, trade groups say in joint petition.
FDA’s Guidance Document To-Do List Grows
Since releasing its annual guidance agenda in December, FDA has added a number of guidances to its development agenda.
FDA Transparency Initiative: GSK's Tailored Comments Seek To Shape Plan
FDA's transparency initiative has drawn sharp criticism from drug industry organizations fearful that trade secrets will be divulged, but GlaxoSmithKline is taking a different tack in suggesting modifications rather than condemning them outright